INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $32.45 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $32.54, a 62.55% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $86.88, a 2.21% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $85.00, a 15.52% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $100.62, a 106.02% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $59.97, a 14.63% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $70.25, a 4.94% decline from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $73.90, a 19.73% increase from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $61.72, a 100.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.45 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $32.54 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $59.97 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $60.27 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $68.50 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $86.88 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $70.25 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $71.23 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $77.99 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $85.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $73.90 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $80.20 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $95.52 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $100.62 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $61.72 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $59.08 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $51.76 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $48.84 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $30.74 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $29.80 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $27.85 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $20.71 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $18.41 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $18.21 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $16.82 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $16.23 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $18.50 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $18.45 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $18.79 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $19.45 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $16.59 10-K · filed 2019-02-27 | |||
| 2018-06-30 | $15.79 10-Q · filed 2018-08-01 | |||
| 2018-03-31 | $14.62 10-Q · filed 2018-05-01 | |||
| 2017-12-31 | $12.55 10-K · filed 2018-03-14 | |||
| 2017-09-30 | $13.02 10-Q · filed 2017-10-31 | |||
| 2017-06-30 | $13.69 10-Q · filed 2017-08-01 | |||
| 2017-03-31 | $16.03 10-Q · filed 2017-05-02 | |||
| 2016-12-31 | $15.34 10-K · filed 2017-03-14 | |||
| 2016-09-30 | $6.52 10-Q · filed 2016-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |